Van Strum & Towne Inc. continued to hold its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, Holdings Channel reports. The institutional investor owned 88,181 shares of the company’s stock at the end of the second quarter. Teva Pharmaceutical Industries Limited accounts for 1.9% of Van Strum & Towne Inc.’s holdings, making the stock its 24th largest position. Van Strum & Towne Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $2,929,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. Sii Investments Inc. WI raised its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock valued at $214,000 after buying an additional 25 shares during the period. Salem Investment Counselors Inc. raised its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock valued at $267,000 after buying an additional 32 shares during the period. Cribstone Capital Management LLC raised its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the period. Financial Architects Inc raised its stake in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares during the period. Finally, Sterling Investment Advisors Ltd. raised its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares during the period. 56.27% of the stock is currently owned by institutional investors.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 17.30 on Friday. The company’s 50-day moving average price is $29.64 and its 200 day moving average price is $31.56. Teva Pharmaceutical Industries Limited has a 1-year low of $16.81 and a 1-year high of $55.39. The firm’s market cap is $17.58 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 EPS. On average, analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -18.95%.

COPYRIGHT VIOLATION WARNING: “Van Strum & Towne Inc. Has $2,929,000 Position in Teva Pharmaceutical Industries Limited (TEVA)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://theolympiareport.com/2017/08/12/van-strum-towne-inc-has-2929000-position-in-teva-pharmaceutical-industries-limited-teva.html.

Several analysts recently weighed in on the company. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, June 22nd. Vetr lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $31.05 price objective on the stock. in a research note on Thursday, June 22nd. BidaskClub raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Wednesday, July 5th. Maxim Group reaffirmed a “hold” rating and issued a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has a consensus rating of “Hold” and an average price target of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.